+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 5 Actively Recruiting clinical trials

A

Actively Recruiting

Researchers are collecting and evaluating data on various Abbott vascular medical devices used in clinical procedures. This prospective, non-randomized, open-label, multi-center registry aims to confirm the safety and performance of these devices over their expected lifetime. The study also focuses on monitoring risks, detecting new risks based on real evidence, ensuring the benefit-risk balance remains acceptable, and identifying any misuse or off-label use to verify appropriate device use. Participants receive one or more Abbott vascular devices, such as coronary and peripheral stents, pacing catheters, vascular plugs, measurement and imaging tools including FFR and OCT, peripheral and coronary dilatation catheters, guidewires, vessel closure or compression devices, and vascular access introducers. The study covers multiple device types used during vascular procedures performed as part of routine clinical care. During the study, researchers collect clinical data throughout and after the procedures, monitoring outcomes like death, myocardial infarction, target lesion revascularization, amputations, procedural complications, device success, and safety issues. Follow-up assessments occur at procedure time, 30 days, and 12 months to evaluate these outcomes. Participants are followed according to the specified schedule, which may include data collection on clinical events and device performance over time.

Age: 18Years +All Genders
37 locations
G

Actively Recruiting

This research aims to gather more information on the safety, effectiveness, and performance of the DynamX Coronary Bioadaptor System in treating patients with ischemic heart disease caused by new native coronary artery lesions. It focuses on a real-world patient population with coronary artery disease to confirm how well this device works and its safety when used in routine medical care. All participants in the study will receive at least one implant of the DynamX Novolimus-eluting Coronary Bioadaptor System during a percutaneous coronary intervention PCI procedure. The device will be used following the products instructions in a commercial setting. This registry monitors the devices performance and outcomes over time without altering the usual care process. During the study, patients will be followed to assess clinical outcomes such as device success, procedural success, and various cardiovascular events including myocardial infarction, revascularization, stroke, and death. These outcomes will be tracked at hospital stay, 30 days, and 12 months after the procedure. The study also collects data on the duration of dual antiplatelet therapy DAPT and will monitor device safety and effectiveness throughout the follow-up period, which extends up to 12 months and beyond.

Age: 18Years +All Genders
17 locations
P

Actively Recruiting

Researchers are collecting real-world data on the BioFreedom Ultra CoCr Biolimus A9 Coated Coronary Stent System in patients who have undergone percutaneous coronary intervention PCI. This prospective, observational registry study involves up to 10,000 patients treated at up to 150 cardiology centers across Europe, South America, the Middle East, and Asia over five years. The study provides post-market clinical follow-up as part of ongoing post-market surveillance. Participants receive the BioFreedom Ultra device, which consists of a cobalt chromium stent platform coated on the outside with the active ingredient BA9, without polymer or carrier. The study observes the use of this device in standard clinical practice without altering patient care. Patients are monitored mainly through telephone or clinic visits one year after PCI. During the study, participants will be followed for 12 months to collect data on outcomes such as target lesion failure, clinically driven target lesion revascularization, cardiovascular death, target vessel myocardial infarction, target vessel revascularization, and stent thrombosis. Follow-up assessments are conducted primarily by phone, ensuring safety monitoring and data collection in a real-world setting with minimal disruption to participants routine care.

Age: 18Years +All Genders
10 locations
G

Actively Recruiting

This research aims to collect real-world data on patients with type 2 diabetes, hypertension, heart failure, and chronic kidney disease. It focuses on understanding patient characteristics, disease management, healthcare use, and outcomes across many countries. The study is an observational registry that includes patients seen in regular clinical practice worldwide. Participants are grouped based on their main condition or comorbidities, including type 2 diabetes, hypertension, chronic kidney disease, or heart failure. Data is collected both retrospectively and prospectively using a cloud-based electronic case report form accessible to investigators and a scientific committee. The registry is open to all physicians managing these conditions globally. Participants contribute information about their health status, treatments, and clinical measurements over time. Researchers gather demographic data, disease history, lab tests, imaging, medication use, healthcare visits, and outcomes such as hospitalizations and complications. The study measures many health indicators at baseline and averages over three years to understand care quality and disease progression. Participation can last until the study ends in 2030.

Age: 18Years +All Genders
76 locations
S

Actively Recruiting

Researchers are studying the effects of dupilumab treatment on mental health, specifically anxiety and depression symptoms, as well as quality of life in patients with moderate-to-severe atopic dermatitis AD. The study focuses on patients already receiving dupilumab, aiming to observe how this treatment impacts their psychological well-being and life quality over time. Participants will be observed during a 6-month period while continuing their dupilumab therapy as prescribed by their doctors in real-world clinical settings. The study does not administer any treatments but monitors patients who start dupilumab within 30 days before enrollment. The enrollment period for the study will last about 9 months. Throughout the study, participants will complete assessments measuring anxiety and depression levels using the Hospital Anxiety and Depression Scale HADS and quality of life via tools like the Patient-Oriented Eczema Measure POEM and Dermatology Life Quality Index DLQI. Researchers will evaluate changes from baseline to week 24 in these scores and monitor professional and psychological impacts. The study aims to better understand the mental health outcomes of patients receiving dupilumab over six months.

Age: 12Years +All Genders
7 locations